📢 Latest Announcements：Pharmasaga is currently seeking interns for its Clinical Research and Research & Development Departments. Students majoring in biology, chemistry, or life sciences are encouraged to apply. 👉 Click here for internship details and application instructions.

2025 pre-Emerging Stock Market Listing Investor Conference

Pharmasaga Management Team

2025 pre-Emerging Stock Market Listing Investor Conference

Group Photo of Distinguished Guests and All Staff

2025 Taipei BioTech Award

Showcasing our excellence in research and development

2025 U.S. BIO

Connecting with the global biotech industry

Competing for the Championship
at the U.S. BIO
Start-Up Stadium

Pharmasaga: One of Only Two Selected Teams from Asia

U.S. BIO
International Vendor Discussions

Expanding international partnership relationships

Pharmasaga

About Us

Pharmasaga was established in January 2021 as a spin-off from Academia Sinica, licensing the research findings of Dr. Wen-Ching Yang's laboratory over more than a decade regarding PS1. PS1 effectively inhibits the Pdia4 protein, which plays a key role in diabetes. Data shows it can prevent beta-cell failure and stabilize blood sugar.

About Pharmasaga

Competing for the Championship

The US BIO Exhibition is a global biotechnology event. We were honored to be selected for the Start-up Stadium competition, designed for top-tier technologies. Among the 57 global finalists, Pharmasaga was one of only two selected teams from Asia.

Join Pharmasaga

Academia Sinica Spin-off

The core technology originates from the development platform of Dr. Wen-Ching Yang, aimed at developing novel targets and first-in-class diabetes drugs. We are committed to conducting clinical trials for PS1, with a vision of providing patients with a cure, reducing pain and social burdens.

Investors

Core Technology & Latest Updates

Core Technology

Academia Sinica first discovered and identified the novel diabetes target PDIA4, and utilized a molecular docking technology platform to identify lead compounds that inhibit PDIA4. This led to the development of PS-001, a potential first-in-class small-molecule novel drug for the diabetes market. Our company has obtained the exclusive global license for this technology from Academia Sinica, which serves as the core technology for our drug development.

R&D

Pharmasaga

Clinical Trial Volunteer Recruitment: PS-001 Novel Diabetes Drug

Pharmasaga's core technology PS-001 has entered Phase I clinical trials. This trial is conducted by the Taipei Medical University Hospital, aiming to evaluate safety and potential efficacy.

Core Recruitment Criteria:

Age between 18 and 80, gender not restricted
Body mass index (BMI) between 18.5 and 40.0 kg/m²
No other major diseases or medical history except type 2 diabetes
Glycated hemoglobin (HbA1c) between 5.7% and 9.0%, or fasting blood glucose between 100 and 250 mg/dL
Willing to comply with all procedures and restrictions of the clinical trial

* This recruitment advertisement has been approved by the Taipei Medical University Joint Institutional Review Board. For detailed information, please click the button below.

Clinical Trial Details

* https://e-sub.fda.gov.tw/ClinicalTrialInfo/case-search/PS1-01

View Registration and Contact Information

* https://e-sub.fda.gov.tw/ClinicalTrialInfo/case-search/PS1-01

News

Contact Us

Pharmasaga
Phone number : + 886-2-27938665
E-mail : contact@pharmasaga.com
Address : 22 F.-1, No. 93, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221416, Taiwan (R.O.C.)